NUCKS1 Acts As A Promising Novel Bio-Marker in The Prognosis of Patients with Hepatocellular Carcinoma

Abstract

Background: Nuclear casein kinase and cyclin-dependent kinase substrate 1 (NUCKS1) was over-expressed in some tumors, including hepatocellular carcinoma (HCC). However, the clinical significance of NUCKS1 in HCC was still unclear. The aim of this study was to explore the expression and prognostic value of NUCKS1 in HCC. Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the relative mRNA expression of NUCKS1 in HCC tissues and corresponding adjacent normal tissues. The relationship between NUCKS1 expression and clinical characteristics of patients was analyzed by c2 test. Kaplan-Meier method and cox regression analysis were applied to estimate the prognostic value of NUCKS1 in HCC. Results: Compared with normal tissues, the relative mRNA expression level of NUCKS1 was significantly up-regulated in HCC tissues (P < 0.001). And high NUCKS1 expression was closely associated with tumor differentiation, TNM stage, vascular invasion and metastasis (P < 0.05). Kaplan-Meier analysis revealed that the overall survival of HCC patients with low expression of NUCKS1 was obviously longer than those with high NUCKS1 expression (log rank test, P = 0.001). NUCKS1 was an independent prognostic factor of HCC patients via univariate and multivariate cox regression analyses.Conclusions: NUCKS1 may be correlated with the progression of HCC and may serve as a potential factor for the prognosis of this disease.

Bioinformatics analysis of differentially expressed genes in non alcoholic fatty liver disease using next generation sequencing data

“…A miRNA-hub gene regulatory network and TF-hub gene regulatory network were constructed with hub genes, and then miRNAs and TFs were identified. CDT1 [687], ZWINT (ZW10 interacting kinetochore protein) [688], hsa-mir-3613-3p [689], GATA2 [690], RUNX1 [691], SUZ12 [692], NUCKS1 [693], FOXP2 [694], TP53 [695], AHR (aryl hydrocarbon receptor) [696] and TRIM28 [697] were revealed to be correlated with disease outcome in patients with hepatocellular carcinoma. Hsa-mir-199a-5p [698], hsa-mir-22-5p [699], hsamir-338-5p [700], GATA2 [701], RUNX1 [702], SUZ12 [703], TP53 [704] and AHR (aryl hydrocarbon receptor) [705] were revealed to be associated with cardiovascular diseases, but these molecular markers might be novel targets for NAFLD.…”